Tailored therapy offers new hope for tough T-Cell leukemia
Disease control
Not yet recruiting
This study tests whether choosing treatments based on each patient's cancer cell behavior can improve remission rates for people with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL). About 93 participants aged 15 and older will receive either a personalized dru…
Phase: PHASE2 • Sponsor: Philippe ROUSSELOT • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC